hit counter
Catalyst Biosciences, Inc. (CBIO) Stock News Sentiment & Price - Sentifly
CBIO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Catalyst Biosciences, Inc. (CBIO)

USA
Biotechnology
NASDAQ
CBIO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CBIO Latest news
GlobeNewsWire
Neutral
Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences
2021-10-29 08:00

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., chief scientific officer, will present at two upcoming scientific conferences, the 5th Complement-based Drug Development Summit, being held October 26-28, 2021, and the American Society for Biochemistry and Molecular Biology's (ASBMB) Serine Proteases in Pericellular Proteolysis and Signaling Virtual Meeting, being held October 28-30, 2021. Catalyst will provide an overview of the Company's ProTUNE™ platform, and its ability to engineer Complement Factor I (CFI) for potency and specificity in complement-mediated disorders.

Zacks Investment Research
Negative
Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2021-10-28 16:49

Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
Catalyst Biosciences Announces Chief Financial Officer Transition
2021-10-13 16:05

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal reasons effective October 29, 2021. Seline Miller, the Company's controller, has been promoted to senior vice president, finance and will serve as interim chief financial and principal accounting officer while the Company initiates a search for a successor.

Benzinga
Positive
Catalyst Biosciences' Lead Candidate Secures Orphan Drug Tag For Blood Clotting Disorder
2021-09-29 07:23

The FDA has granted Orphan Drug Disease Designation to Catalyst Biosciences Inc's (NASDAQ: CBIO) Marzeptacog alfa (activated), or MarzAA, for Factor VII Deficiency (FVIID).  Factor VII deficiency is a blood clotting disorder that causes excessive or prolonged bleeding after an injury or surgery.

GlobeNewsWire
Neutral
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
2021-09-28 16:01

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Disease Designation (ODD) for its lead product candidate, subcutaneous Marzeptacog alfa (activated), or MarzAA, for the treatment of Factor VII Deficiency (FVIID). MarzAA was previously granted ODD and Fast Track Designation (FTD) for treatment of Hemophilia A/B with inhibitors and FTD for the treatment of FVIID.

GlobeNewsWire
Neutral
Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
2021-09-24 08:00

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that a fireside chat including members of its executive management team will be broadcast as part of the Cantor Global Healthcare Conference at 10:00 am ET on Wednesday, September 29, 2021.

Zacks Investment Research
Positive
Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates
2021-08-05 12:10

Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of 5.88% and 13.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update
2021-08-05 08:00

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2021, and provided a corporate update.

Zacks Investment Research
Negative
Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2021-07-29 16:44

Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies
2021-07-22 08:00

Launching the ConFIrm study to identify patients with Complement Factor I deficiencies Launching the ConFIrm study to identify patients with Complement Factor I deficiencies

Loading more news...